Price T Rowe Associates Inc. MD Has $5.60 Million Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Price T Rowe Associates Inc. MD grew its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 7.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,357 shares of the company's stock after purchasing an additional 4,263 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.07% of HealthEquity worth $5,600,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Wealthfront Advisers LLC acquired a new stake in shares of HealthEquity during the fourth quarter worth about $10,304,089,000. Vanguard Group Inc. lifted its position in HealthEquity by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company's stock valued at $861,256,000 after acquiring an additional 99,624 shares during the last quarter. FMR LLC boosted its position in shares of HealthEquity by 2.4% in the 4th quarter. FMR LLC now owns 5,415,800 shares of the company's stock valued at $519,646,000 after purchasing an additional 125,684 shares during the period. Geode Capital Management LLC increased its holdings in shares of HealthEquity by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,089,398 shares of the company's stock valued at $200,522,000 after acquiring an additional 10,421 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of HealthEquity by 0.7% in the third quarter. Franklin Resources Inc. now owns 1,640,215 shares of the company's stock valued at $139,369,000 after buying an additional 11,659 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total transaction of $446,487.50. Following the completion of the sale, the director now owns 84,969 shares of the company's stock, valued at $6,597,842.85. This represents a 6.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of HealthEquity stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the transaction, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,381 shares of company stock valued at $1,781,432. Insiders own 2.20% of the company's stock.

HealthEquity Stock Down 1.3 %

Shares of HQY traded down $1.15 during trading hours on Tuesday, reaching $90.27. The company's stock had a trading volume of 702,629 shares, compared to its average volume of 784,542. The firm has a market cap of $7.81 billion, a price-to-earnings ratio of 82.81, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average of $88.93 and a two-hundred day moving average of $96.62. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $115.59.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. KeyCorp cut their price target on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Barrington Research reissued an "outperform" rating and set a $112.00 price target on shares of HealthEquity in a research report on Friday, April 11th. Wells Fargo & Company raised their target price on shares of HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Raymond James upgraded HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their price target for the company from $120.00 to $115.00 in a report on Tuesday, March 25th. Finally, The Goldman Sachs Group reduced their target price on HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $111.75.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.